Bulk Inquiry
CADD522
Axon 3394
CAS:
199735-88-1
Purity:
98%
- Soluble in 0.1N NaOH(aq), DMSO and EtOH
- MF: C15H13Cl2NO3
- MW: 326.17
Description
CADD522 is a potent inhibitor of RUNX2-DNA binding with an IC50 value of 10 nM. In vitro and in vivo studies reveal that CADD522 suppresses breast cancer growth and metastasis. Additionally, CADD522 inhibits mitochondrial oxidative phosphorylation by decreasing the mitochondrial oxygen consumption rate (OCR) and ATP production in human breast cancer cells in a RUNX2-independent manner.
More Information
| Parent CAS No. | 199735-88-1 |
|---|---|
| Chemical Name | 3-(3,4-Dichlorophenylcarbamoyl)bicyclo[2.2.1]hept-5-ene-2-carboxylic acid |
| SMILES | C12C(C(=O)NC3C=C(Cl)C(Cl)=CC=3)C(C(O)=O)C(C1)C=C2 |
| MFCD | N.A. |
| InChi | InChI=1S/C15H13Cl2NO3/c16-10-4-3-9(6-11(10)17)18-14(19)12-7-1-2-8(5-7)13(12)15(20)21/h1-4,6-8,12-13H,5H2,(H,18,19)(H,20,21) |
| InChiKey | YSDNWNOGHQYWPK-UHFFFAOYSA-N |
| CID | 2834870 |
| Short Description | RUNX2-DNA inhibitor |
References
- MS Kim et al. Characterization of CADD522, a small molecule that inhibits RUNX2-DNA binding and exhibits antitumor activity. Oncotarget. 2017 Aug 10;8(41):70916-70940.
- MS Kim et al. Targeting breast cancer metabolism with a novel inhibitor of mitochondrial ATP synthesis. Oncotarget. 2020 Oct 27;11(43):3863-3885.
